Printed From BioPortfolio.com
Boehringer Ingelheim and Sarah Cannon Research Institute to Investigate Novel Immuno-Oncology Combination Therapy
10:31 EDT 30 Oct 2017 | Speciality Pharma Journal
INGELHEIM, Germany & NASHVILLE, Tenn.–(BUSINESS WIRE)–Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology therapies. The new effort combines Boehringer Ingelheim’s oncology research and Sarah Cannon’s expertise in clinical trial design and recruitment to evaluate BI 891065, a …
Original Article: Boehringer Ingelheim and Sarah Cannon Research Institute to Investigate Novel Immuno-Oncology Combination Therapy
